2017 Rapid Desensitization for Delayed Reactions to Chemotherapy and Monoclonal Antibodies

Saturday, 8 December 2012
Hall 4 (HICC)

Maria Aranzazu Vega Castro, MD , Allergy Service, Hospital Universitario De Guadalajara, Guadalajara, Spain

Ana María Alonso, MD , Allergy Service, Hospital Universitario De Guadalajara, Guadalajara, Spain

Juan María Beitia, MD , Allergy Service, Hospital Universitario De Guadalajara, Guadalajara, Spain

Maria Belén Mateo, PhD , Allergy Service, Hospital Universitario De Guadalajara, Guadalajara, Spain

Remedios Cardenas, MD , Allergy Servicce, Hospital General De Ciudad Real, Ciudad Real, Spain

Background:

Drug desensitization is the induction of temporary clinical unresponsiveness to drug antigens to which patients have presented severe hypersensitivity reactions (HSR). Rapid desensitization in patients suffering immediate hypersensitivity reactions with chemotherapeutic agents and monoclonal antibodies have been widely described and have shown to be successful. Non-immediate hypersensitivity reactions with other drugs have usually required desensitization with several days’ protocols to achieve total doses. 

Methods:

Thirty-eight desensitization procedures were performed in 5 patients with a 12-13 step, 6-hour protocol. All patients had developed a delayed maculopapular rash with the use of chemotherapeutic and/or biological agents. Three patients were pretreated with corticosteroids, paracetamol and antihistamines before each desensitization procedure.

Results:

All the 38 desensitizations undertaken were successfully completed (25 with Temozolamide, 4 with Bendamustine, 4 with Rituximab and 5 with Infliximab). We observed HSR during 8 (21%) of desensitizations, including 5 inmediate  exantema and 3 delayed local macular exantema. Two patients were treated with corticosteroids and anti-histamines after the desensitization protocol to avoid more delayed HSR.

Conclusions:

Rapid desensitization protocols are safe and effective in getting over delayed  HSR to chemotherapeutic and monoclonal antibodies and allow patients with severe diseases to continue their treatment.